Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies - Summary - MDSpire

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies

  • By

  • Franciska Otaner

  • Vratko Himic

  • Luis O. Vargas

  • Matthew Abikenari

  • Neelesh Pandey

  • Shayndhan Sivanathan

  • Olivia Kalmanson

  • Aparna Govindan

  • Diane Jung

  • Dagoberto Estevez-Ordonez

  • Amy Wang

  • Sanjeeva Jeyaretna

  • Ashish H. Shah

  • Ricardo J. Komotar

  • Bradley Gampel

  • Christine Dinh

  • Michael E. Ivan

  • May 16, 2026

Share

Objective:

To review the genetic and epigenetic pathways underlying vestibular schwannomas (VS) and evaluate clinical trials targeting these mechanisms, emphasizing their potential impact on treatment outcomes.

Key Findings:
  • Approximately 90% of VS are sporadic, with NF2-related cases being the primary genetic association, indicating a need for targeted genetic screening.
  • Loss of merlin activates multiple signaling pathways that drive Schwann cell proliferation and survival, suggesting potential therapeutic targets.
  • Epigenetic regulation plays a significant role in VS biology, influencing tumor behavior and patient outcomes, which may inform treatment strategies.
  • Current therapeutic options, including bevacizumab, show modest effects, highlighting the urgent need for improved treatment strategies that consider genetic and epigenetic insights.
Interpretation:

The behavior of vestibular schwannomas is influenced by a combination of genetic alterations and epigenetic modifications, which may contribute to hearing loss and other clinical features, necessitating a multifaceted treatment approach.

Limitations:
  • Limited progress in translating molecular insights into consistent clinical benefits, particularly in the context of personalized medicine.
  • Gaps in integrating genetic and epigenetic knowledge into patient stratification and treatment design, which could enhance therapeutic efficacy.
Conclusion:

A comprehensive understanding of the genetic and epigenetic landscape of VS is crucial for developing targeted therapies and improving patient outcomes, particularly regarding hearing preservation, which is vital for quality of life.

Original Source(s)

Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies

  • by Franciska Otaner, Vratko Himic, Luis O. Vargas, Matthew Abikenari, Neelesh Pandey, Shayndhan Sivanathan, Olivia Kalmanson, Aparna Govindan, Diane Jung, Dagoberto Estevez-Ordonez, Amy Wang, Sanjeeva Jeyaretna, Ashish H. Shah, Ricardo J. Komotar, Bradley Gampel, Christine Dinh, Michael E. Ivan

  • May 16, 2026

Related Content